Burning Rock Biotech (BNR) vs ICON (ICLR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Burning Rock Biotech (BNR) has outperformed ICON (ICLR) over the past year, gaining 70.8% versus a loss of 11.8%. Over five years, ICLR leads with a -40.2% price change compared with -89.4% for BNR. ICON is the larger company by market cap ($12.69 billion vs $160.3 million), about 79.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNR | ICLR |
|---|---|---|
| Share price | $15.20 | $164.50 |
| Market cap | $160.30M | $12.69B |
| 1-day change | +0.13% | +0.26% |
| YTD return | -24.57% | -9.72% |
| 1-year return | +70.79% | -11.79% |
| 5-year return | -89.42% | -40.19% |
| P/E ratio (TTM) | — | 173.16 |
| Forward P/E | — | 13.93 |
| EPS (TTM) | $-0.80 | $0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.25B |
| Revenue growth (YoY) | — | +0.76% |
| Net income (latest FY) | — | $229.34M |
| Gross margin | — | 26.37% |
| Operating margin | — | 5.37% |
| Net margin | — | 2.78% |
| 52-week high | $41.72 | $203.91 |
| 52-week low | $6.79 | $66.57 |
| Distance from 52-week high | -63.57% | -19.33% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +12.10% |
| Average volume | 28.59K | 822.57K |
| Shares outstanding | 8.81M | 77.15M |
| Employees | 667 | 40,200 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 79.2 times larger than Burning Rock Biotech by market value ($12.69B vs $160.30M).
- BNR has outperformed ICLR by 82.6 percentage points over the past year.
About Burning Rock Biotech
BNR stock →Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Health Care · Medical Specialities · 667 employees
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
BNR vs ICLR FAQ
Which is bigger, Burning Rock Biotech or ICON?
ICON (ICLR) is larger, with a market capitalization of $12.69B compared with $160.30M for Burning Rock Biotech (BNR).
Which stock has performed better over the past year, BNR or ICLR?
BNR returned +70.79% over the past 12 months, compared with -11.79% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Are Burning Rock Biotech and ICON in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Burning Rock Biotech and Biotechnology: Commercial Physical & Biological Resarch for ICON.